Wegovy-maker Novo Nordisk presented new data on Wednesday showing its experimental weight-loss pill improved blood sugar ...

Discover why Hims & Hers Health (HIMS) remains a strong long-term buy after robust Q3 growth, new offerings, and expansion ...

Hims & Hers Health narrowed its full-year guidance following mixed third-quarter results as the telehealth platform continued to post strong subscriber and revenue growth.

Shares of Hims & Hers Health ($HIMS) rallied on Tuesday after management said it’s in discussions with Novo Nordisk ($NVO) to ...

Market observers now await further developments regarding the potential Novo Nordisk partnership. Should Hims & Hers successfully secure the Wegovy distribution agreement, the company could maintain ...

Hims & Hers Health (NYSE:HIMS) said it is holding discussions with Novo Nordisk (NYSE:NVO) to make the Danish drugmaker's ...

Hims and Hers Health Inc. rose after the telehealth company said it was in talks with Novo Nordisk A/S to sell its ...

Hims & Hers Health (HIMS) stock rises as the company renews talks with Novo Nordisk (NVO) to sell the pharma giant's obesity drug Wegovy. Read more here.

This article was reviewed by Darragh O’Carroll, MD. Oral vs. Injectable Semaglutide: Effectiveness & Side Effects Key ...

Telehealth company Hims & Hers Health Inc. said late Monday it is in “active discussions” with Denmark’s Novo Nordisk A/S to ...

Dow Jones Top Company Headlines at 5 AM ET: Saudi Aramco's Net Profit Rises on Higher Production, Oil Prices | BP ... Third-quarter profit rose compared with the prior three-month period but declined ...